eMedicine from WebMD
 

eMedicine Specialties > Oncology > Carcinomas of the Lung and Other Intrathoracic Carcinomas

Pancoast Syndrome

Karl J D'Silva, MD, Fellow in Hematology/Oncology, Department of Internal Medicine, Breslin Cancer Center, Michigan State University
Sarah K May, MD, Consulting Staff, Department of Hematology-Oncology, Caritas Carney Hospital, Commonwealth Hematology-Oncology PC

Updated: Aug 26, 2008

Introduction

Background

Pancoast syndrome is characterized by a malignant neoplasm of the superior sulcus of the lung (lung cancer) with destructive lesions of the thoracic inlet and involvement of the brachial plexus and cervical sympathetic nerves (stellate ganglion). This is accompanied by (1) severe pain in the shoulder region radiating toward the axilla and scapula along the ulnar aspect of the muscles of the hand, (2) atrophy of hand and arm muscles, (3) Horner syndrome (ptosis, miosis, hemianhidrosis, enophthalmos), and (4) compression of the blood vessels with edema.

In 1924, Henry Pancoast, a radiologist from the University of Pennsylvania, published his first paper describing tumors of the pulmonary apex.1 In a 1932 report, he described in greater detail the syndrome that now bears his name.2 Medical historians note that Hare published a report in 1838 that may have included the first description of tumors of the superior sulcus.3

Pathophysiology

The overwhelming majority of cases of Pancoast syndrome are non–small cell lung carcinoma (NSCLC), with more than 95% located in the superior sulcus. The most common varieties are squamous cell carcinoma or adenocarcinoma. Small cell carcinoma is observed in fewer than 5% percent of cases in most series.

Other causes include nonepithelial neoplasms (eg, lymphoid malignancies, metastatic cancers of nonpulmonary causes), infections, lymphomatoid granulomatosis, vascular aneurysms, amyloid nodules, and cervical rib syndrome. Inflammatory pseudotumor (plasma cell granuloma), mycotic subclavian artery aneurysm, and carotid pseudoaneurysm in a child (caused by a hydatid cyst) have been reported. Because of the wide variety of diseases that can produce Pancoast syndrome, a histologic diagnosis is mandatory before initiating definitive treatment.

Frequency

United States

Pancoast tumors are uncommon and comprise fewer than 5% of all lung cancers.4,5 Originally deemed universally fatal, Pancoast tumors are now amenable to curative treatment because of improvements in combined modality therapy and development of new techniques for resection.

Mortality/Morbidity

For neoplastic causes, predictors of 5-year survival are weight loss, supraclavicular fossa or vertebral body involvement, disease stage, and surgical treatment. A study by an MD Anderson group reported the following findings:6

  • For patients with stage IIB disease, the 5-year survival rate was 47%, while those with stage IIIA or IIIB disease had survival rates of 14% and 16%, respectively.
  • In patients with stage IIB disease, surgical treatment and weight loss were significant independent predictors of 5-year survival.
  • Among patients with stage IIIA disease, the only predictor of survival was the Karnofsky performance score.
  • In patients with stage IIIB disease, the only independent predictor of survival was a right superior sulcus location, which was associated with a worse 5-year survival rate than that of patients with tumors in the left superior sulcus.
  • Compared with patients who had squamous cell tumors, more patients with adenocarcinoma had cerebral metastases within 5 years.

Clinical

History

Patients with Pancoast tumor (Pancoast’s tumor, an uncommon subset of lung cancer) may present with referred pain over the scapula to the shoulder as the result of damage to the afferent pain fibers of the sympathetic trunk. Pain in an ulnar nerve distribution along the medial aspect of the arm to the fingers results from involvement of the lower brachial plexus, the eighth cervical nerve, and the first thoracic nerve. This may be associated with hand weakness.

Many patients are initially treated for presumed local musculoskeletal conditions such as bursitis and vertebral osteoarthritis with radicular pain. Symptoms may persist for many months before evaluation for progression reveals the cause. In a 1994 series by Maggi and colleagues, symptoms lasted 2-36 months, with a mean of 9.7 months.7 In 1997, Muscolino described plexopathy or radicular symptoms in 53% of 15 patients.8

Physical

Physical examination of patients with Pancoast tumor (Pancoast’s tumor, an uncommon subset of lung cancer) may reveal findings consistent with Horner syndrome, such as ptosis and miosis, which result from paralysis of the dilating sympathetic fibers. Supraclavicular lymphadenopathy may also be observed.

Horner syndrome (Horner’s syndrome) is the result of invasion of the lower cervical and first thoracic ganglia, which frequently fuse into a single ganglion, the stellate ganglion. Horner syndrome is observed in 20-50% of patients at presentation.4,7,8,9 Decreased sweating on the affected side and ptosis of the denervated lid may be observed. Application of topical cocaine to the miotic eye (contracted pupil) fails to cause pupil dilation, while appropriate dilation is noted in the unaffected eye.10

The tumor may invade the bony structures of the chest. The first or second thoracic vertebra or the first, second, or third ribs may be invaded. In a review of 60 patients with Pancoast tumors, Maggi and associates found radiographic evidence of rib erosion in 50%; an almost equal percentage demonstrated involvement of the first or second rib, and 20% had involvement of the third rib. One patient had involvement of all 3 ribs.7 The tumor can also invade the first or second thoracic vertebral bodies or intervertebral foramina. From this point, it can extend to the spinal cord and result in cord compression. The subclavian vein or artery may also be invaded.

Cough, dyspnea, and hemoptysis, which are signs often associated with lung cancer, are not as common in individuals with Pancoast syndrome because of the peripheral location of the tumor. When present, they are associated with a worse prognosis. Also uncommon but occasionally noted are more advanced tumors with involvement of the recurrent laryngeal nerve, phrenic nerve, or superior vena cava.

See related CME at Examining the Eyes of an Older Person.

Causes

Non–small cell lung cancer is the most common etiology of Pancoast syndrome (Pancoast's syndrome); adenocarcinoma, squamous cell carcinoma, and large cell carcinoma have all been observed. Overall, Pancoast tumors are uncommon and comprise fewer than 5% of all lung cancers.4,5 While non–small cell lung cancer is the most common cause of Pancoast syndrome, the list of differential diagnoses is broad. Although quite rare, small cell lung cancer is also observed. Maggi and colleagues reported only 3 patients with small cell carcinoma in their 1994 series of 60 patients.7 More typically, small cell carcinoma manifests in a central location rather than a peripheral.

A diverse variety of unusual causes may be involved. Rarely, benign tumors such as desmoid tumors (case records of the Massachusetts GeneralHospital: weekly clinicopathological exercises, 2000) or hemangiopericytoma11 may cause the condition. Adenoid cystic carcinoma,12 metastatic carcinoma,13 lymphoma,14 and thyroid carcinoma15  have all been associated with the syndrome. Infectious processes, including bacterial16,17 and fungal infections18,19 may also be involved.

Differential Diagnoses

Lung Cancer, Non-Small Cell
Lung Cancer, Oat Cell (Small Cell)

Workup

Imaging Studies

  • Imaging and biopsy are the cornerstones of evaluation of Pancoast tumor (Pancoast's tumor, an uncommon subset of lung cancer).
  • The apex of the lung can be difficult to investigate because it is bounded laterally by the first rib, posteriorly by the first rib and the vertebral bodies, and anteriorly by the costal cartilage of the first rib and the manubrium. Plain radiographs of the chest frequently show no change or an asymmetry or thickening of the apical cap. Apical lordotic films may be more revealing. CT scans and MRIs have become standard imaging techniques.
  • CT scans are less expensive than MRIs and much more available. CT scans can help assess bone destruction, and they are useful in the general imaging of the lung for the evaluation of mediastinal adenopathy, other pulmonary nodules, and liver involvement. MRIs may be more accurate in evaluating chest wall invasion, examining vascular structures, and assessing the brachial plexus for invasion.20,21,22
  • Additional staging studies should be considered. Mediastinoscopy should be performed to evaluate mediastinal nodes. The presence of N2 mediastinal lymphadenopathy has a significant adverse effect on survival. A CT scan or MRI of the head to exclude occult metastasis should be performed if treatment with curative intent is planned. A CT scan of the chest can be extended to include the liver and adrenal glands.
  • Since positron-emission tomography (PET) scanning is US Food and Drug Administration–approved for staging of non–small cell lung cancer in general, it is also being used in the setting of Pancoast syndrome.

Procedures

  • Tissue diagnosis should be performed. However, if a patient presents with supraclavicular lymph node enlargement, then a fine-needle aspiration biopsy of enlarged supraclavicular lymph nodes or an ipsilateral supraclavicular fullness procedure is a fast, safe, and inexpensive means of confirming the diagnosis.
  • Sputum cytology results are positive in fewer than 15% of patients.23 Fiberoptic bronchoscopy findings are more often positive, but only in 20-30% of patients, because of the peripheral location of the tumor.24 Bronchoscopy, however, can be useful in excluding otherwise unsuspected concurrent endobronchial lesions.
  • Transthoracic needle biopsy by CT guidance has a high yield, up to 95% in some series.25,23,26 Some tumors may be evaluated only by thoracotomy, either open or video assisted.

Staging

The American Joint Committee on Cancer (AJCC) and the Union Internationale Contre le Cancer (UICC) have adopted the International System for Staging Lung Cancer.27 This classification stages lung cancers by describing tumor characteristics and tumor distribution.

The T designation describes the size and invasiveness of the primary tumor. T3 indicates a tumor of any size that invades the chest wall (the parietal pleura). T4 is a tumor of any size that invades the vertebral body, neural or vascular structure, mediastinum, esophagus, or trachea.

The N designation describes the distribution of positive lymph nodes. N1 indicates metastasis to ipsilateral peribronchial or hilar nodes. N2 indicates the spread to ipsilateral mediastinal and/or subcarinal nodes. N3 indicates metastasis to nodes of the contralateral hilar and mediastinal areas or scalene or supraclavicular nodes, either ipsilateral or contralateral.

The M designation describes the extent of distant metastasis. M0 indicates no identifiable metastatic disease, and M1 designates the presence of distant metastasis (eg, brain, bone, liver). Any M1 findings indicate stage IV disease.

AJCC Stages for Pancoast Tumors

StageT (Tumor)N (Nodes)
IIBT3N0
IIIAT3N1
T3N2
IIIBAny TN3
T4Any N

Attar and coworkers reviewed their experience with 105 patients treated from 1955-1997. They found that 30% of patients presented with T3 N0 disease (stage IIB), 26% with T4 N0 (stage IIIA), and 25% with metastatic disease (M1, stage IV). In their review of 124 patients, Ginsberg and colleagues found that 58% of patients had T3 N0 disease, 16% had T3 N2, and only 1% had T3 N1. In addition, 6% of patients had T3 N3 disease, 18% had T4 N0, and 1% had T4 N.4

Treatment

Medical Care

In patients with a Pancoast tumor (Pancoast’s tumor, an uncommon subset of lung cancer), a multimodality approach seems to be optimal, involving chemoradiotherapy and surgical resection, provided appropriate staging has been conducted. Patients with central T4 tumors that do not have mediastinal node involvement are uncommon. Such patients, however, seem to benefit from resection as part of the treatment as opposed to chemoradiotherapy alone when carefully staged and selected.

Today, in accordance with Rusch and colleagues' 2001 trial findings, most centers use cisplatin-based chemotherapy with etoposide and concurrent radiotherapy as neoadjuvant treatment, followed by surgical resection, as the standard of care for this group of patients.28 One cautionary note is that this trial mandated a negative mediastinoscopy result. The preoperative radiotherapy dose was 4500 cGy in 25 fractions.

Surgical Care

  • Historically, Pancoast tumors (Pancoast’s tumor, an uncommon subset of lung cancer) have been difficult to treat. In the 1950s, they were considered inoperable.
    • In 1956, Chardack and MacCallum reported the first 5-year survival of a patient treated with resection and postoperative radiation therapy.
    • The combination of radiation and surgery was further evaluated, and, in 1961, Shaw and Paulson published a report of 18 patients treated with preoperative radiation therapy and surgical resection. They found a significant increase in resectability and cure; thereafter, preoperative radiation followed by surgery became the standard of care.29
  • In many centers, the current practice is to individualize a treatment plan for each patient. Frequently, treatment decisions are made by a multidisciplinary thoracic oncology group with attention to adverse prognostic factors.
    • The surgical treatment of choice is complete removal of the tumor by en bloc chest wall resection combined with lobectomy and node staging.4 Depending upon the extent of local invasion, surgical treatment may require resection of the paravertebral sympathetic chain, stellate ganglion, lower trunks of the brachial plexus, subclavian artery, or portions of the thoracic vertebrae.
    • Radiation and chemotherapy may benefit local and systemic control by addressing individual adverse findings.
    • In many centers, neoadjuvant or induction chemoradiotherapy is administered to patients with potentially resectable tumors. Important factors include T category, nodal status, presence of Horner syndrome, and completeness of resection.4,30,31,5,8,9 Surgery is generally undertaken 2-4 weeks after the completion of radiation therapy.
    • For tumors that invade the brachial plexus, the spine, or both, a combined thoracic-neurosurgical approach is warranted.
  • A lung intergroup trial (SWOG 0220) is studying induction therapy with cisplatin, etoposide, and radiotherapy with 45 Gy, followed by resection if possible, and postoperative docetaxel.

Medication

The goals of pharmacotherapy for Pancoast tumor (Pancoast’s tumor, an uncommon subset of lung cancer) are to induce remission, reduce morbidity, and prevent complications.

Antineoplastic agents

These agents inhibit cell growth and proliferation. Treat head, neck, breast, testicular, and ovarian cancer; Hodgkin and non-Hodgkin lymphoma; neuroblastoma; sarcomas; bladder, gastric, lung, esophageal, cervical, and prostate cancer; myeloma; melanoma; mesothelioma; small cell lung cancer (SCLC); osteosarcoma; acute nonlymphoblastic leukemia (ANLL); hepatoma; rhabdomyosarcoma, mycosis fungoides, uterine carcinoma, histiocytosis; gestational trophoblastic disease; Ewing sarcoma, Kaposi sarcoma, Wilms tumor, and brain tumors.


Cisplatin (Platinol)

Alkylating agent causing intrastrand and interstrand cross-linking of DNA, leading to strand breakage. Has broad range of antitumor activity. Forms backbone of currently available approved combination chemotherapy regimens for NSCLC and SCLC that cause Pancoast syndrome.
Administered by IV infusion in isotonic sodium chloride solution (0.9%) or sodium chloride and glucose. The manufacturers recommend that higher doses be administered in 2 L of chloride-containing infusion fluid over at least 1-2 h and that an infusion time of 6-8 h may further reduce toxicity. In practice, volumes of less than 2 L have been used in expert centers. To aid diuresis and protect the kidneys, 37.5 g of mannitol (eg, 375 mL of mannitol [10%]) is usually added to the infusion, or is infused separately, immediately before cisplatin. In order to initiate diuresis, the patient is usually hydrated by the infusion of 1-2 L of a suitable fluid over several hours before the administration of cisplatin. Adequate hydration must also be maintained for up to 24 h after a dose. Renal, hematological, auditory, and neurological function should be monitored during therapy and administration adjusted accordingly.

Dosing

Adult

PE (cisplatin-etoposide) regimen: 25 mg/m2 IV on days 1-3 of cycle; repeat q3-4wk for 4-6 cycles

Pediatric

Not established

Interactions

Increases toxicity of bleomycin and ethacrynic acid; other nephrotoxic drugs (eg, aminoglycosides, amphotericin B, cyclosporine) increase nephrotoxicity; bleomycin, cytarabine, methotrexate, and ifosfamide may accumulate owing to decreased renal excretion; may worsen cytotoxicity of etoposide; mesna and sodium thiosulfate directly inactivate cisplatin; dipyridamole increases cytotoxicity by enhancing cellular uptake; paclitaxel-related peripheral neuropathy may be increased in patients previously treated with cisplatin

Contraindications

Documented hypersensitivity; preexisting renal insufficiency; myelosuppression; hearing impairment

Precautions

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Administer adequate hydration before and for 24 h after cisplatin dosing to reduce risk of nephrotoxicity; myelosuppression, ototoxicity, nausea, and vomiting may occur; peripheral blood cell counts and serum electrolyte levels should be monitored; requires close monitoring of pretreatment creatinine level and CrCl and posttreatment magnesium levels; neurologic examination should be performed regularly; major dose-limiting toxic effect is peripheral neuropathy; can cause acute or chronic renal failure in up to one third of patients treated, but this can usually be prevented by vigorous hydration and saline diuresis; renal tubular wasting of potassium and magnesium is common (monitor closely); cellulitis and fibrosis have rarely occurred after extravasation; avoid aluminum needles


Etoposide (Toposar, VePesid)

A semisynthetic derivative of podophyllotoxin with antineoplastic properties; it interferes with the function of topoisomerase II, thus inhibiting DNA synthesis, and is most active against cells in the late S and G(2) phases of the cell cycle.

Dosing

Adult

PE regimen: 100 mg/m2 IV on days 1-3 of cycle; repeat q3-4wk for 4-6 cycles; administer by slow IV infusion, over at least 30 min, as a solution in isotonic sodium chloride solution (0.9%) or glucose (5%) injection
Single-agent regimen: 50 mg PO bid for days 1-14 of cycles; repeat cycle q3-4wk for 4-6 cycles; adjust dose in hepatic or renal dysfunction
Total bilirubin (TB) = 1.5-3 mg/dL: 50% dose reduction
TB = 3.1-4.9 mg/dL: 75% dose reduction
TB > 5 mg/dL: Avoid use
CrCl = 15-50 mL/min: 25% dose reduction

Pediatric

Not established

Interactions

May prolong effects of warfarin and increase clearance of methotrexate; cyclosporine has additive effects in cytotoxicity of tumor cells; high dose of cyclosporine (serum concentration >2000 ng/mL) decreases clearance, leading to increased risk of neutropenia; zidovudine increases serum concentration, resulting in increased toxicity

Contraindications

Documented hypersensitivity; IT administration (may cause death)

Precautions

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Bleeding, severe myelosuppression, nausea, vomiting, hypotension, allergic reaction, and alopecia may occur; reduce dose in hepatic (eg, increased TB) or renal (eg, decreased CrCl) impairment

Follow-up

Prognosis

  • Prognosis for Pancoast tumor (Pancoast’s tumor, an uncommon subset of lung cancer) is stage dependent.
    • Attar and coworkers reported a median survival of 36.8 months in patients with T3 lesions undergoing combined modality treatment; median survival was only 6.4 months if the patient had T4 disease.9
    • Vertebral body invasion is generally associated with a poor prognosis.
    • Newer surgical approaches may prove beneficial. In 1993, Dartevelle and colleagues presented their experience with an anterior transcervical thoracic approach that permitted greater exposure and control of the vascular structures of the thoracic inlet, which facilitated resection in situations in which vascular structures were invaded.32
    • The presence of Horner syndrome (Horner’s syndrome) and nodal involvement are associated with an inferior prognosis.
    • Overall survival data were summarized by Detterbeck, who noted that 5-year survival rates ranged from 15-56%.31 Of the 104 patients treated by Attar and coworkers, 7 (~7%) were 5-year survivors and 3 (~3%) were 10-year survivors.9 Another study demonstrated surgical morbidity rates of 7-38%, with mortality ranging from 5-10%.30
  • Analysis of patterns of failure may help suggest alternate treatment strategies.
    • Locoregional relapse is common despite preoperative or postoperative radiation therapy. Muscolino and coworkers found locoregional recurrence in 60% of patients treated with a combined radiosurgical approach. Ginsberg and associates found that 94 of their 124 patients had recurrence of disease, with 72% of these cases being locoregional at initial recurrence. In two thirds of patients who underwent complete resection, local recurrences were the first site of relapse.4
    • This distribution of relapses was noted in several studies reviewed by Detterbeck. In many of these studies, patients received preoperative radiation therapy.31 In the Memorial Sloan-Kettering experience, additional postoperative brachytherapy was administered to achieve maximal possible local control; despite these measures, local relapses, and, ultimately, distant relapses, were frequent.4
  • Distant disease limits survival. The brain is the frequent site of failure for superior sulcus tumors. The authors recommend careful surveillance for brain metastasis during and after the therapy. The authors also recommend obtaining brain imaging prior to surgery in patients receiving induction therapy for the primary tumor.

Patient Education

For excellent patient education resources, visit eMedicine's Cancer and Tumors Center and Hand, Wrist, Elbow, and Shoulder Center. Also, see eMedicine's patient education articles Lung Cancer and Shoulder and Neck Pain.

Miscellaneous

Medicolegal Pitfalls

Failure to make the diagnosis of a Pancoast tumor (Pancoast’s tumor, an uncommon subset of lung cancer) is a potential source of medicolegal liability. Primary care physicians, rheumatologists, orthopedic surgeons, and neurosurgeons must be aware of this possibility, particularly in patients who smoke.

Special Concerns

  • Future directions
    • While preoperative radiation followed by complete en bloc resection is an advance over previous treatment paradigms, the high frequency of local recurrence despite aggressive measures coupled with the eventual development of distant disease and death prompt continued exploration of novel approaches.
    • The introduction of chemotherapy into the treatment plan and newer modes of radiation therapy bring the possibility of additional progress. Since Pancoast tumors are an uncommon subset of lung cancer, the number of cases has been insufficient to justify conclusions; however, new approaches to the general treatment of patients with regionally advanced disease (T3, chest wall invasion) are undergoing evaluation with chemotherapy, both with and without radiation therapy.
    • Since a major concern for overall survival is systemic control, the patient is given immediate therapy that may reduce micrometastatic disease.
    • Several early trials demonstrated survival benefits in small groups of patients (not Pancoast patients) with locally advanced lung cancer treated with preoperative chemotherapy.33,34 The largest study of this kind, reported by Albain and coworkers, reported complete pathologic responses in 21% of surgical patients following preoperative concurrent chemotherapy and radiation therapy.35 The optimal chemotherapeutic regimen has not yet been identified, and newer agents may improve responses.36
    • Ultrasound-guided cervical nerve roots ablation can be considered for patients with intractable neuropathic pain secondary to Pancoast tumor. Anecdotal studies have shown patients had excellent pain relief as well as improvement in quality of sleep.
  • Summary
    • Pancoast syndrome induces pain in the shoulder, scapula, or arm and is sometimes associated with Horner syndrome (Horner’s syndrome). Pancoast syndrome results from a tumor of the pulmonary apex, most often a non–small cell lung cancer.
    • Preoperative radiation therapy has improved resectability rates, and the addition of preoperative chemotherapy, with radiation therapy, holds the possibility of additional improvements in resectability and ultimate cure. Adverse prognostic findings include Horner syndrome, invasion of major vascular structures or vertebral bodies, N2 or N3 disease, and incomplete resection.
    • Patients with superior sulcus tumors should be encouraged to enroll in prospective clinical trials so that the optimal therapy can be determined.

References

  1. Pancoast HK. Importance of careful roentgen ray investigations of apical chest tumors. JAMA. 1924;83:1407-1411.

  2. Pancoast HK. Superior pulmonary sulcus tumor: Tumor characterized by pain, Horner's syndrome, destruction of bone and atrophy of hand muscles. JAMA. 1932;99:1391-1396.

  3. Hare ES. Tumor involving certain nerves. Lond Med Gaz. 1838;1:16-18.

  4. Ginsberg RJ, Martini N, Zaman M, et al. Influence of surgical resection and brachytherapy in the management of superior sulcus tumor. Ann Thorac Surg. Jun 1994;57(6):1440-5. [Medline].

  5. Johnson DE, Goldberg M. Management of carcinoma of the superior pulmonary sulcus. Oncology (Huntingt). Jun 1997;11(6):781-5; discussion 785-6. [Medline].

  6. Komaki R, Roth JA, Walsh GL, et al. Outcome predictors for 143 patients with superior sulcus tumors treated by multidisciplinary approach at the University of Texas M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys. Sep 1 2000;48(2):347-54. [Medline].

  7. Maggi G, Casadio C, Pischedda F, et al. Combined radiosurgical treatment of Pancoast tumor. Ann Thorac Surg. Jan 1994;57(1):198-202. [Medline].

  8. Muscolino G, Valente M, Andreani S. Pancoast tumours: clinical assessment and long-term results of combined radiosurgical treatment. Thorax. Mar 1997;52(3):284-6. [Medline].

  9. Attar S, Krasna MJ, Sonett JR, et al. Superior sulcus (Pancoast) tumor: experience with 105 patients. Ann Thorac Surg. Jul 1998;66(1):193-8. [Medline].

  10. Balcer LJ, Galetta SL. Images in clinical medicine. Pancoast's syndrome. N Engl J Med. Nov 6 1997;337(19):1359. [Medline].

  11. Chong KM, Hennox SC, Sheppard MN. Primary hemangiopericytoma presenting as a Pancoast tumor. Ann Thorac Surg. Feb 1993;55(2):9. [Medline].

  12. Hatton MQ, Allen MB, Cooke NJ. Pancoast syndrome: an unusual presentation of adenoid cystic carcinoma. Eur Respir J. Feb 1993;6(2):271-2. [Medline].

  13. Amin R. Bilateral Pancoast's syndrome in a patient with carcinoma of the cervix. Gynecol Oncol. May 1986;24(1):126-8. [Medline].

  14. Mills PR, Han LY, Dick R, Clarke SW. Pancoast syndrome caused by a high grade B cell lymphoma. Thorax. Jan 1994;49(1):92-3. [Medline].

  15. Rabano A, La Sala M, Hernandez P, et al. Thyroid carcinoma presenting as Pancoast's syndrome. Thorax. Apr 1991;46(4):270-1. [Medline].

  16. Vandenplas O, Mercenier C, Trigaux JP, et al. Pancoast's syndrome due to Pseudomonas aeruginosa infection of the lung apex. Thorax. Sep 1991;46(9):683-4. [Medline].

  17. Gallagher KJ, Jeffrey RR, Kerr KM, Steven MM. Pancoast syndrome: an unusual complication of pulmonary infection by Staphylococcus aureus. Ann Thorac Surg. May 1992;53(5):903-4. [Medline].

  18. Simpson FG, Morgan M, Cooke NJ. Pancoast's syndrome associated with invasive aspergillosis. Thorax. Feb 1986;41(2):156-7. [Medline].

  19. Mitchell DH, Sorrell TC. Pancoast's syndrome due to pulmonary infection with Cryptococcus neoformans variety gattii. Clin Infect Dis. May 1992;14(5):1142-4. [Medline].

  20. Beale R, Slater R, Hennington M, Keagy B. Pancoast tumor: use of MRI for tumor staging. South Med J. Dec 1992;85(12):1260-3. [Medline].

  21. Patz EF Jr. Imaging lung cancer. Semin Oncol. Oct 1999;26(5 Suppl 15):21-6. [Medline].

  22. Heelan RT, Demas BE, Caravelli JF, et al. Superior sulcus tumors: CT and MR imaging. Radiology. Mar 1989;170(3 Pt 1):637-41. [Medline].

  23. Anderson TM, Moy PM, Holmes EC. Factors affecting survival in superior sulcus tumors. J Clin Oncol. Nov 1986;4(11):1598-603. [Medline].

  24. Maxfield RA, Aranda CP. The role of fiberoptic bronchoscopy and transbronchial biopsy in the diagnosis of Pancoast''s tumor. N Y State J Med. Jun 1987;87(6):326-9. [Medline].

  25. Paulson DL, Weed TE, Rian RL. Cervical approach for percutaneous needle biopsy of Pancoast tumors. Ann Thorac Surg. Jun 1985;39(6):586-7. [Medline].

  26. Shaham D. Semi-invasive and invasive procedures for the diagnosis and staging of lung cancer. I. Percutaneous transthoracic needle biopsy. Radiol Clin North Am. May 2000;38(3):525-34. [Medline].

  27. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. Jun 1997;111(6):1710-7. [Medline].

  28. Rusch VW. Management of Pancoast tumours. Lancet Oncol. Dec 2006;7(12):997-1005. [Medline].

  29. Shaw RR, Paulson DL, Kee JL. Treatment of Superior Sulcus Tumor by Irradiation Followed by Resection. Ann Surg. Jul 1961;154(1):29-40. [Medline].

  30. Arcasoy SM, Jett JR. Superior pulmonary sulcus tumors and Pancoast's syndrome. N Engl J Med. Nov 6 1997;337(19):1370-6. [Medline].

  31. Detterbeck FC. Pancoast (superior sulcus) tumors. Ann Thorac Surg. Jun 1997;63(6):1810-8. [Medline].

  32. Dartevelle PG, Chapelier AR, Macchiarini P, et al. Anterior transcervical-thoracic approach for radical resection of lung tumors invading the thoracic inlet. J Thorac Cardiovasc Surg. Jun 1993;105(6):1025-34. [Medline].

  33. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. Jan 20 1994;330(3):153-8. [Medline].

  34. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. May 4 1994;86(9):673-80. [Medline].

  35. Albain KS, Crowley JJ, Turrisi AT, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol. Aug 15 2002;20(16):3454-60. [Medline].

  36. Langer CJ. Induction or neoadjuvant therapy in resectable non-small cell lung cancer. Semin Oncol. Oct 1999;26(5 Suppl 15):34-9. [Medline].

  37. Barnes JB, Johnson SB, Dahiya RS, et al. Concomitant weekly cisplatin and thoracic radiotherapy for Pancoast tumors of the lung: pilot experience of the San Antonio Cancer Institute. Am J Clin Oncol. Feb 2002;25(1):90-2. [Medline].

  38. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 18-2000. A 45-year-old woman with a thoracic mass and Pancoast's syndrome. N Engl J Med. Jun 15 2000;342(24):1814-21. [Medline].

  39. Chardack WM, MacCallum JD. Pancoast tumor: Five-year survival without recurrence or metastases following radical resection and postoperative irradiation. J Thorac Surg. 1956;31:535-542.

  40. Gofeld M, Bhatia A. Alleviation of Pancoast's Tumor Pain by Ultrasound-Guided Percutaneous Ablation of Cervical Nerve Roots. Pain Pract. May 23 2008;[Medline].

  41. Gofeld M, Bhatia A. Alleviation of Pancoast's Tumor Pain by Ultrasound-Guided Percutaneous Ablation of Cervical Nerve Roots. Pain Pract. May 23 2008;[Medline].

  42. Huehnergarth KV, Lipsky BA. Superior pulmonary sulcus tumor with Pancoast syndrome. Mayo Clin Proc. Oct 2004;79(10):1268. [Medline].

  43. Junker K, Langner K, Klinke F, et al. Grading of tumor regression in non-small cell lung cancer : morphology and prognosis. Chest. Nov 2001;120(5):1584-91. [Medline].

  44. Landreneau RJ, Mack MJ, Dowling RD, et al. The role of thoracoscopy in lung cancer management. Chest. Jan 1998;113(1 Suppl):6S-12S. [Medline].

  45. Marra A, Eberhardt W, Pottgen C, et al. Induction chemotherapy, concurrent chemoradiation and surgery for Pancoast tumour. Eur Respir J. Jan 2007;29(1):117-26. [Medline].

  46. Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg. Mar 2001;121(3):472-83. [Medline].

  47. Sartori F, Rea F, Calabro F, et al. Carcinoma of the superior pulmonary sulcus. Results of irradiation and radical resection. J Thorac Cardiovasc Surg. Sep 1992;104(3):679-83. [Medline].

  48. Shah H, Anker CJ, Bogart J, et al. Brain: the common site of relapse in patients with pancoast or superior sulcus tumors. J Thorac Oncol. Nov 2006;1(9):1020-2. [Medline].

  49. Shen KR, Meyers BF, Larner JM, et al. Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. Sep 2007;132(3 Suppl):290S-305S. [Medline].

  50. Socinski MA, Crowell R, Hensing TE, et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. Sep 2007;132(3 Suppl):277S-289S. [Medline].

  51. Wright CD, Moncure AC, Shepard JA, et al. Superior sulcus lung tumors. Results of combined treatment (irradiation and radical resection). J Thorac Cardiovasc Surg. Jul 1987;94(1):69-74. [Medline].

Keywords

Pancoast syndrome, Pancoast’s syndrome, lung cancer, Horner syndrome, Horner’s syndrome, shoulder pain, superior sulcus tumor, Ciuffini-Pancoast syndrome, Ciuffini-Pancoast-Tobías syndrome, Hare's syndrome, Pancoast's apex syndrome, Pancoast's disease, Pancoast's pain syndrome, Pancoast-Tobías syndrome, Tobías' syndrome, Bernard-Horner syndrome, ptosis, miosis, hemianhidrosis, anhidrosis, enophthalmos, non–small cell lung cancer, NSCLC, non–small cell bronchogenic carcinoma, squamous cell carcinoma, SCC, adenocarcinoma, Pancoast tumor, Pancoast’s tumor, malignant neoplasm

Contributor Information and Disclosures

Author

Karl J D'Silva, MD, Fellow in Hematology/Oncology, Department of Internal Medicine, Breslin Cancer Center, Michigan State University
Karl J D'Silva, MD is a member of the following medical societies: Massachusetts Medical Society
Disclosure: Nothing to disclose.

Coauthor(s)

Sarah K May, MD, Consulting Staff, Department of Hematology-Oncology, Caritas Carney Hospital, Commonwealth Hematology-Oncology PC
Disclosure: Nothing to disclose.

Medical Editor

Michael Perry, MD, MS, MACP, Nellie B Smith Chair of Oncology, Professor, Department of Internal Medicine, Division of Hematology and Oncology, University of Missouri at Columbia/Ellis Fischel Cancer Center
Michael Perry, MD, MS, MACP is a member of the following medical societies: Alpha Omega Alpha, American Association for Cancer Research, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Medical Association, American Society of Hematology, Missouri State Medical Association, Southern Association for Oncology, and Southern Medical Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Benjamin Movsas, MD, Vice-Chairman, Department of Radiation Oncology, Fox Chase Cancer Center
Benjamin Movsas, MD is a member of the following medical societies: American College of Radiology, American Radium Society, and American Society for Therapeutic Radiology and Oncology
Disclosure: Nothing to disclose.

CME Editor

Rajalaxmi McKenna, MD, FACP, Consulting Staff, Department of Medicine, Southwest Medical Consultants, SC, Good Samaritan Hospital, Advocate Health Systems
Rajalaxmi McKenna, MD, FACP is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology, and International Society on Thrombosis and Haemostasis
Disclosure: Nothing to disclose.

Chief Editor

Jules E Harris, MD, Clinical Professor of Medicine, Division of Hematology/Medical Oncology, Department of Internal Medicine, University of Arizona College of Medicine at Tucson; Consulting Staff, Arizona Cancer Center
Jules E Harris, MD is a member of the following medical societies: American Association for Cancer Research, American Association for the Advancement of Science, American Association of Immunologists, American Society of Hematology, and Central Society for Clinical Research
Disclosure: GlobeImmune Salary Consulting; Amplimed Consulting fee Consulting

Further Reading

© 1994- by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)